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Purpose: Impairment of subchondral bone density and quality aggravates cartilage damage in osteoar-
thritis (OA). Accordingly, we assessed whether improving microstructure and quality at subchondral
bone by the bone-forming agent parathyroid hormone (PTH) [1-34] prevent cartilage damage progres-
sion in a rabbit model of OA preceded by osteoporosis (OP).
Methods: OP was induced in 20 female rabbits. At week 7, these rabbits underwent knee surgery to
induce OA and, at week 12, they started either saline vehicle (n¼ 10) or PTH (n¼ 10) for 10 weeks. Ten
healthy animals were used as controls. At week 22, microstructure was assessed by micro-computed
tomography and bone remodelling by protein expression of alkaline phosphatase (ALP),
metalloproteinase-9 (MMP9), osteoprotegerin (OPG) and receptor activator of nuclear factor-kB ligand
(RANKL) at subchondral bone. Cartilage damage was evaluated using Mankin score.
Results: PTH reversed the decrease of bone area/tissue area, trabecular thickness, plate thickness, polar
moment of inertia, ALP expression and OPG/RANKL ratio, as well as counteracted the increase of fractal
dimension and MMP9 expression at subchondral bone of osteoarthritis preceded by osteoporosis (OPOA)
rabbits compared to vehicle administration (P< 0.05). Likewise, PTH decreased cartilage damage severity
in OPOA rabbits. Good correlations were observed between subchondral bone structure or remodelling
parameters, and cartilage Mankin score.
Conclusions: Improvement of microstructural and remodelling parameters at subchondral bone by PTH
[1-34] contributed to prevent cartilage damage progression in rabbits with early OPOA. These ﬁndings
support the role of subchondral bone in OA. Further studies are warranted to establish the place of
bone-forming agents as potential treatment in OA.
 2011 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
Osteoarthritis (OA) and osteoporosis (OP) are two skeletal
disorders that most commonly affect the worldwide population1.
While classically an inverse relationship between bone mineral
density (BMD) and OA has been accepted, recent experimental and
clinical research indicate that OP changes in subchondral bone may
play a key role in the initiation of the disease in a subset of knee OA
patients2e8. An intimate biological and mechanical relationshipG. Herrero-Beaumont, Bone
v. Reyes Católicos, 2, 28040
2636.
(M. Bellido), llugo@fjd.es
n-Blas), scastas@gmail.com
s (R. Largo), gherrero@fjd.es
s Research Society International. Poccurs between both articular cartilage and subchondral bone,
being recognized that the mechanical properties of subchondral
bone inﬂuences the integrity of overlaying articular cartilage9e13.
However, lesser consensus exists regarding the effect of OP in
subchondral bone on the progression of cartilage damage in OA,
mainly due to the apparently scarce coexistence of these two very
common skeletal disorders in the same patient14,15. Furthermore,
clinical trials aimed to prevent cartilage damage in patients with
knee OA by enhancing subchondral bone structure have given
contradictory results, in part due to the heterogeneity of the pop-
ulation collected and/or to deﬁciencies in study design16e19.
Therefore, the role of OP subchondral bone in cartilage degradation
during OA is not fully discerned yet20,21.
In order to bring clarity to the relationship between articular
changes and periarticular BMD, the use of animal models experi-
encing both OA and OP without interference from other confusionublished by Elsevier Ltd. All rights reserved.
Fig. 1. Experimental design to study the effect of the improvement of subchondral
bone quality by intermittent PTH [1-34] administration upon the progression of
cartilage damage in a combined rabbit model of early OA aggravated by previous OP.
(A) Experimental scheme. OVX; MPH. (B) Qualitative 2D models were reconstructed
from images selected of a highly representative sample for each group, by using the
CTAn software (Skyscan, Aartselaar, Belgium).
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of low bone mass followed by a destabilization-induced OA in
rabbits, the microstructural impairment of subchondral bone by
increased remodelling has been found to aggravate cartilage
damage9,10, in agreement with the ﬁndings described in murine
models of chemically- and surgically-induced knee OA associated
with ovariectomy (OVX)22e24. Both decreased alkaline phosphatase
(ALP) expression and increased metalloproteinase (MMP) -9
expression, as well as, a dysregulation of the receptor activator of
nuclear factor-kB ligand (RANKL)/RANK/osteoprotegerin (OPG)
pathway were evidenced in the subchondral bone of our experi-
mental model10. Accordingly, numerous alterations in structural
and biomechanical properties have been described in the articular
cartilage of different experimental models of low bone mass
induced by OVX25e28. However, in our combined model was not
possible to discern whether OP elicits a temporarily negative effect
at OA initiation or the negative effect remains during OA
progression.
In this context, we hypothesized that reversing microstructure
and remodelling damage at subchondral bone of our experimental
model of osteoarthritis preceded by osteoporosis (OPOA) by the use
of a bone-forming agent may support the contribution of sub-
chondral bone to OA progression. Previous studies carried out by
our group had shown that surgically-induced instability models of
OA always develop cartilage damage as earlier as 5 weeks after
knee surgery in rabbits29,30. Hereof, the intermittent administration
of parathyroid hormone PTH [1-34], which exerts a clear positive
effect on cancellous bone remodelling by increasing the number
and activity of osteoblasts and decreasing their apoptosis31e35,
starting 5 weeks after surgically-induced OA represents a suitable
therapeutic approach to examine this hypothesis.
Therefore, the present study aimed to assess whether improving
the structure and quality of OP subchondral bone by using an
anabolic agent such as PTH [1-34] during early OA stages avoids
further cartilage damage at experimental OPOA.
Materials and methods
Animals
Thirty female New Zealand rabbits skeletally mature, and
8-month-old (3.8e4.8 kg body weight) were included in the study
(Granja Universal, Pamplona, Spain). The animals were housed
individually in stainless-steel cages and maintained on a 12 h light/
12 h dark cycle at room temperature, becoming acclimatized after
2 weeks. They had free access to water and standard rabbit chow
(Panlab, Barcelona, Spain). The animal handling followed
throughout the study was in accordance with procedures approved
by the Institutional Animal Care and Use Committee, which follows
international regulations.
Experimental animal model
Twenty rabbits underwent to OVX and intramuscular injections
of methylprednisolone hemisuccinate (MPH) (1 mg/kg/day) for
4 weeks to induce OP. Ten age and gender-matched additional
animals were used as controls (healthy group). After 7 weeks, both
knees of OP rabbits went through partial medial meniscectomy and
anterior cruciate ligament (ACL) section, inducing a surgical OA by
destabilization. Surgical procedures, anaesthesia and antibiotic
prophylaxis were carried out according to protocol previously
described9.
At week 12, rabbits with combined OA and OP (OPOA) were
divided in two groups: 10 rabbits were injected with saline solution
[OPOAþvehicle (VEH) group] and other 10 received subcutaneousinjections of PTH [1-34] (teriparatide; 10 mg/kg/day, 5 days weekly;
OPOAþ PTH group). These pharmacological agents were adminis-
tered for 10 weeks. Free cage activity after surgery was allowed to
animals. Twenty-two weeks after OVX, all rabbits were euthanized
by intracardiac administration of sodium pentobarbital (50 mg/kg)
[Fig. 1(A)]. At sacriﬁce, samples of articular cartilage and sub-
chondral bone of each knee were collected for further studies. The
experiments were approved by the local Committee for Animal
Care and Use.
Subchondral bone microstructural study
At the time of sacriﬁce, we extracted cylindrical biopsies of
subchondral bone measuring 9 mm of length by 4 mm in diameter
from femoral condyles with a trepan bur for explantation (Group
Komet, Lemgo, Germany), as previously described10. Then, biopsies
were frozen at 20C for subsequent assessments.
Micro-computerized tomography (mCT; Skyscan 1172; Skyscan,
Aartselaar, Belgium) was used to study the microarchitecture of the
samples. The evaluators were blinded for the treatment received by
group source of each sample. The X-ray source was set at 100 kV
and 100 mA, with a pixel size of 10.9 mm. Four-hundred and ﬁfty
projections were acquired over an angular range of 180 (angular
step of 0.40). Using the reconstruction software NRecon (Skyscan,
Aartselaar, Belgium) based on the Feldkamp algorithm, the image
slices were reconstructed applying corrections for bean hardening
and ring artifacts. The registered datasets were segmented into
binary images using global thresholding methods. The regions of
interest selected were analyzed with CTAn software (Skyscan,
Aartselaar, Belgium) [Fig. 1(B)].
Two-dimensional (2D) variables including tissue area (T.Ar),
bone area (B.Ar), bone area/tissue area fraction (B.Ar/T.Ar%),
trabecular thickness (Tb.Th), trabecular number (Tb.N) and
trabecular separation (Tb.Sp) were determined for selected regions.
Moreover, we assessed the thickness of the ﬁrst layer of sub-
chondral plate (Sb.Th), the fractal dimension (FD) and polar
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previously described10. The thickness of the ﬁrst layer of sub-
chondral plate (Sb.Th) corresponds to the distance between the
subchondral bone edge and the start point of subchondral trabec-
ular bone, FD is a complexity index of bone microarchitecture36,
and Ip is a geometric index of bone strength to resist torsion37.
Furthermore, Ip represents the rotational analogue of mass for
linear motion.
Western-blot analysis
Forty mg of total protein from tibial subchondral bone were
loaded and then resolved on 10% acrylamide-sodium dodecyl
sulphate (SDS) gels. After transfer to polyvinylidene diﬂuoride
(PVDF) membranes (Millipore, Molsheim, France), antibodies
against OPG (R&D Systems, Abingdon, UK), RANKL (Prepotech,
Neuilly-Sur-Seine, France), ALP (Abcam, Cambridge, UK) andMMP9
(Calbiochem/Merck, Nottingham, UK) were used. Brieﬂy, the
membranes were blocked in 5% skimmed milk in phosphate buffer
saline (PBS)-Tween 20 for 1 h at room temperature, and incubated
overnight at 4 C with the primary antibodies. Antibody binding
was detected by enhanced chemiluminescence using
peroxidase-labelled secondary antibodies. The bands were
assessed by densitometry and the results expressed in arbitrary
units (AU), after normalization to glyceraldehyde 3-phosphate
dehydrogenase (GAPDH) levels.
Cartilage histology
Femur and tibia sections, after sacriﬁce, were ﬁxed in buffered
formalin for 24 h and then decalciﬁed for 6 weeks in an ethyl-
enediaminetetraacetic acid (EDTA) solution (2 mM EDTA, 0.5 mM
tartrate sodium potassium, pH 1). The decalciﬁed knee joints were
cleaved in a sagittal plane along the central portion of the articular
surface of each medial femoral condyle corresponding to the
weight bearing area, and following embedded in parafﬁn wax.
Cartilage sections (5 mm) were stained with hematoxylin and eosin
to assess cellularity and structural abnormalities, and with Alcian
blue and safranin O to evaluate matrix abnormalities.
The weight bearing area of femoral condyles, which usually
shows the earliest and most severe histological abnormalities29,
was histopathologically assessed using the Mankin’s grading
system by an experienced cartilage pathologist30. The observer was
blinded for the treatment received by the rabbit group source and
macroscopic description of the samples, which were presented in
random order.
Statistical analysis
Results are expressed as mean 95% conﬁdence interval (95%
CI). ManneWhitney non-parametric analyses were used toTable I
Microstructure parameters at subchondral bone
Healthy (n¼ 7) OPOAþVEH (n¼ 8) OPOAþ PT
Mean 95% CI Mean 95% CI Mean 95
B.Ar/T.Ar% 47.50 9.27 36.28 10.34 45.81 10
Tb.Th (mm) 0.23 0.05 0.17 0.06 0.21 0.
Tb.Sp (mm) 0.24 0.06 0.31 0.10 0.24 0.
Tb.N (no/mm2) 2.35 0.22 2.33 0.25 2.41 0.
Sb.Th (mm) 0.30 0.09 0.06 0.03 0.17 0.
FD (AU) 1.04 0.01 1.07 0.03 1.05 0.
Ip (mm4) 9.18 2.09 6.65 2.44 9.03 1.
P-values were obtained comparing the groups by ManneWhitney test using the two-tai
Differences were considered signiﬁcant when P< 0.05.compare data from multiple groups, as appropriate. Spearman test
was utilized to evaluate different correlations. All statistical anal-
yses were performed using the statistical package for the social
sciences (SPSS) software v 11.0, Chicago, IL, USA. Statistical signiﬁ-
cance was considered as P< 0.05.
Results
PTH reversed microstructural damage at OPOA subchondral bone
Subchondral bone microarchitecture was studied in healthy and
experimental groups (Table I). The healthy group showed higher
B.Ar/T.Ar and Tb.Th than OPOAþVEH group (P¼ 0.002 in both
cases). Notably, PTH treatment increased both B.Ar/T.Ar% and Tb.Th
compared to vehicle administration in OPOA rabbits (P¼ 0.008 and
P¼ 0.019, respectively). Conversely, Tb.Sp was increased in
OPOAþVEH knees respect to healthy ones (P¼ 0.011), while
treatment with PTH decreased Tb.Sp compared to vehicle admin-
istration in OPOA rabbits (P¼ 0.04). Furthermore, PTH restored
these microstructural parameters to values of control group (P¼NS
in all cases). Regarding Tb.N, no difference was found between the
healthy and vehicle-treated OPOA groups (P¼NS), while PTH
increased this parameter when compared to vehicle administration
in OPOA rabbits (P¼ 0.024).
Notably, Sb.Th was diminished markedly in the OPOAþVEH
group compared with the healthy group (P¼ 0.005). In turn, the
microarchitecture index FD was increased, while the
biomechanical-related geometric index Ip was decreased in the
OPOAþVEH group against the healthy group (P¼ 0.002 and
P¼ 0.003, respectively). PTH reversed these effects compared to
vehicle administration in OPOA animals (Sb.Th: P¼ 0.008; FD:
P¼ 0.019; Ip: P¼ 0.008). Furthermore, PTH restored Ip in OPOA
rabbitsþ to healthy values (P¼NS), see Table I.
PTH counteracted the increase of subchondral bone remodelling
Bone remodelling was assessed at subchondral bone in each
group on week 22 (Fig. 2). Subchondral bone formation assayed by
ALP protein expressionwas diminished in the OPOAþVEH group vs
healthy knees (P¼ 0.001). Subchondral bone degradation deter-
mined by MMP9 protein expression was increased signiﬁcantly in
the OPOAþVEH group with regard to healthy knees (P¼ 0.004).
Intermittent PTH counteracted the changes in ALP and MMP9
protein expression at subchondral bone in OPOA rabbits compared
with vehicle administration (P¼ 0.032 and P¼ 0.002, respectively).
PTH increased the OPG/RANKL ratio at subchondral bone
Since the equilibrium between OPG and RANKL plays a crucial
role in bone physiopathology, their subchondral bone protein
expression was assayed in each group by Western-blot (Fig. 3). TheH (n¼ 7) OPOAþVEH vs
healthy
OPOAþ PTH vs
OPOAþVEH
OPOAþ PTH vs
healthy
% CI P-value P-value P-value
.17 0.002 0.008 0.465
04 0.002 0.019 0.372
07 0.011 0.040 0.465
18 0.908 0.024 0.465
03 0.005 0.008 0.006
01 0.002 0.019 0.007
68 0.003 0.008 0.935
led level.
Fig. 2. ALP and MMP9 protein expression at subchondral bone. At top: densitometric analysis of ALP and MMP9 protein expression at subchondral bone represented in AU. Bar
represents the mean 95% CI. * P< 0.05 vs healthy, & P< 0.05 vs OPOAþVEH. At bottom: representative Western-blot images of ALP and MMP9 for 40 mg of total subchondral bone
protein. The number of rabbits assayed for ALP expressionwere: healthy (n¼ 8); vehicle-treated OPOA (n¼ 10), and PTH-treated OPOA (n¼ 8), and for MMP9 expressionwere: n¼ 6
in each group.
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healthy control knees (P< 0.001), and PTH showed a tendency to
reverse this decrease in OPOA rabbits (P¼NS). Besides, an
increased RANKL expression was found in the OPOAþVEH groupFig. 3. OPG and RANKL protein expression at subchondral bone. Densitometric analysis of
OPG and RANKL are shown. Data in the graph are displayed as AU. Bar represents the mean
total protein from subchondral bone was used for healthy (n¼ 8), vehicle-treated OPOA (n(P¼ 0.024), while no difference occurred between PTH-treated and
vehicle-treated OPOA animals (P¼NS). Furthermore, we have
assessed the OPG/RANKL ratio ﬁnding a decrease in the
vehicle-treated OPOA group when compared to the healthy groupOPG, RANKL and OPG/RANKL ratio, as well as, representative Western-blot images for
 95% CI. * P< 0.05 vs healthy, & P< 0.05 vs OPOAþVEH. To perform the blot, 40 mg of
¼ 10) and PTH-treated OPOA (n¼ 8) groups.
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increase in the OPG/RANKL ratio compared to vehicle-treated OPOA
group (P¼ 0.001), though different from the control ratio.
PTH decreased cartilage damage
Because early lesions in articular cartilage are present at week 5
after OA induction by combining a partial medial meniscectomy
and ACL transection (ACLT) in a rabbit model29,30, PTH treatment
was started at that time point in the current study. Thus, this
pharmacological intervention has been considered as preventive
for further OA progression. Vehicle-treated OA knees in ovariecto-
mized rabbits showed signiﬁcantly higher overall Mankin scores
than healthy knees (P¼ 0.003). Moreover, PTH treatment decreased
the scores compared with vehicle administration in OPOA knees
(P¼ 0.026), although without achieving healthy values [Fig. 4(A)].
Safranin O-stained histological sections of femoral articular
cartilage from healthy rabbits showed homogeneous and intense
staining of proteoglycans at extracellular matrix, normal cellularity
and structure across the different layers [Fig. 4(B)]. In turn, knee
cartilage from vehicle-treated OPOA animals exhibited clearly
reduced safranin O staining of extracellular matrix, hypocellularity
and structural abnormalities across the cartilage, when compared
with the healthy group [Fig. 4(C)]. In knee joints from PTH-treated
OPOA group, the articular cartilage displayed improvement in
cellularity and cellular organization in chondron-like fashion,
although there was some diffuse hypercellurarity, when compared
with vehicle-treated OPOA animals. There was also reduction of
structure irregularities and mild improvement of extracellular
matrix staining [Fig. 4(D)].Fig. 4. Histopathological assessment of cartilage damage. (A) Total Mankin score of histolog
rabbits. Healthy (n¼ 6 rabbits), vehicle-treated OPOA (n¼ 6 rabbits) and PTH-treated OPOA
P< 0.05 vs OPOAþVEH. (BeD) Safranin O staining of representative histological sections of
shows homogeneous and intense staining of proteoglycans at extracellular matrix, normal
cartilage exhibits clearly reduced safranin O staining of extracellular matrix, hypocellulari
displays improvement in cellularity and cellular organization in chondron-like fashion, altho
animals, There is also reduction of structure irregularities and superﬁcial pannus, and mildCorrelations between structural and remodelling parameters at
subchondral bone with cartilage damage
Structural parameters were signiﬁcantly related between
themselves. Thus, B.Ar/T.Ar% was directly related with Sb.Th and Ip
at subchondral bone (P< 0.001), whereas FD was inversely related
with other structural parameters (P< 0.001). Likewise, signiﬁcant
relationships were found between the remodelling marker ALP and
B.Ar/T.Ar% (P< 0.05), FD (P< 0.001), or MMP9 expression (P< 0.05)
at subchondral bone. Remarkably, correlations between structure
or remodelling parameters at subchondral bone and cartilage
damage score were signiﬁcant (P< 0.05 for Ip andMMP9; P< 0.001
for B.Ar/T.Ar%, Sb.Th, FD and ALP, respectively), with the exception
of the OPG/RANKL ratio (P¼NS) (Table II).
Discussion
In the present study, an improvement of microstructure and
quality at subchondral bone by the use of the anabolic bone agent
PTH [1-34] intermittently administeredwas evidenced in the rabbit
model of early OPOA. Remarkably, this beneﬁcial action on sub-
chondral bone exerted from an early stage of OA prevented further
aggravation on the Mankin score and safranin O-stained histolog-
ical sections of articular cartilage. Although discrepancies have
been raised about the subchondral changes originated by the
coexistence of OP and OA in same individuals14,15, a negative effect
of low bone mass upon articular cartilage integrity has been
described in different animal models of OP25e28. Furthermore, we
have recently demonstrated that subchondral bone impairment
originated by an increased remodelling aggravated cartilage injuryical cartilage evaluation at weight bearing area of the medial femoral condyle of knee
(n¼ 6 rabbits) groups. Results are expressed as mean 95% CI. * P< 0.05 vs healthy, &
femoral rabbit articular cartilage with magniﬁcation 100. (B) Healthy: Knee cartilage
cellularity and structure across the different cartilage layers. (C) OPOAD VEH: Knee
ty and structural abnormalities across the cartilage. (D) OPOAD PTH: Knee cartilage
ugh there is some diffuse hypercellularity, when compared with placebo-treated OPOA
improvement of extracellular matrix staining.
Table II
Correlations between structural, biomechanical-related geometric, remodelling and molecular parameters at subchondral bone and cartilage damage score
B.Ar/T.Ar% Sb.Th FD Ip ALP MMP9 OPG/RANKL MANKIN
B.Ar/T.Ar% 1.000
Sb.Th 0.570** 1.000
FD 0.791** 0.595** 1.000
Ip 0.952** 0.486* 0.782** 1.000
ALP 0.601* 0.316 0.720** 0.524 1.000
MMP9 0.545 0.299 0.755** 0.573 0.594* 1.000
OPG/RANKL 0.165 0.119 0.389 0.064 0.217 0.273 1.000
MANKIN 0.639** 0.629** 0.745** 0.552* 0.739** 0.671* 0.358 1.000
*Correlation is signiﬁcant at the 0.05 level (two-tailed).
**Correlation is signiﬁcant at the 0.001 level (two-tailed).
Correlation coefﬁcients were obtained comparing healthy, vehicle-treated OPOA and PTH-treated OPOA groups by Spearman bivariate analysis.
MANKIN: cartilage histopathological Mankin grading score.
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mice and rat models of knee OA associated with OP strongly
support the involvement of subchondral bone plate in OA22e24.
The negative impact of previous OP on themicrostructure of knee
subchondral bone during early stages of OA in rabbits was counter-
acted by the treatmentwith the bone-forming agent initiated atweek
5 after joint surgery in this study. Indeed, intermittent administration
of PTH [1-34] increased B.Ar/T.Ar%, Tb.Th and Sb.Th, as well as,
decreased Tb.Sp. Furthermore, the decrease of FD following PTH
treatment in OPOA animals suggests that the knee subchondral
bone in PTH-treated animals was less porous than that in the
vehicle-treated group. Likewise, the subchondral bone architectural
efﬁciency to resist torsion loads, as evaluated by the Ip, was restored
after intermittent administration of PTH [1-34] in knees of OPOA
rabbits. Therefore, the anabolic agent PTH exerted a beneﬁcial effect
in OPOA subchondral bone structure/geometry, particularly in the
subchondral plate, which is closely related with the overlaying joint
cartilage and plays a signiﬁcant role in OA development13,38e40.
The treatment with the bone-forming agent reversed the
predominance of resorption over formation in the subchondral
bone remodelling of knees in OPOA rabbits. Indeed, as expected,
PTH administration enhanced subchondral bone formation as
assessed by the rise of subchondral ALP expression. Hence, at
subchondral bone, PTH shifted the bone turnover rate to a positive
balance and subsequently improved bone architecture/geometry.
Both bone turnover and bone architecture are major determinants
of bone quality41. Therefore, the bone-forming agent PTH admin-
istered at early stage of OA contributed to improve subchondral
bone quality, previously impaired by OP effect. Thus, an enhanced
subchondral bone quality provided appropriate biomechanical
support and biological link for the overlaying articular cartilage in
rabbits with early OPOA.
Beneﬁcial effects on subchondral bone remodelling have been
also described for antiresorptive drugs in OA without OP. Previous
studies clearly showed that bisphosphonates inhibit effectively the
early increase in subchondral bone resorption in the rat ACL tran-
sectionmodel of OA5, preserve the periarticular trabecular bonemass
and reduce the formation of both osteophytes and bone marrow
lesions in murine models of OA42,43. Similar ﬁndings have been
reported for calcitonin and estrogen use in different OA experimental
models44e48. In addition, women receiving alendronate or estrogen
had less subchondral bone attrition and bone marrow edema-like
abnormalities in knee magnetic resonance imaging (MRI) than
women receiving placebo16. Oral calcitonin has also reduced serum
levels of C-telopeptide of type I collagen (CTX-I), a marker of bone
resorption, in OA patients during a phase I study49. These positive
effects of bisphosphonates, estrogen or calcitonin in OA may be
related to their antiresorptive actions on the microstructure and
remodelling of subchondral bone at OA initiation50,51. In contrast, our
studyassessed the role of establishedOPsubchondral boneduringOAprogression by enhancing bone quality following the administration
of a bone-forming agent, PTH [1-34].
The precise mechanisms accounting for the bone anabolic
actions of PTH [1-34] have not been fully elucidated. However, it is
known that both PTH and PTH-related peptide (PTHrP) signal
through the PTH1 receptor (PTH1R), activating the same signalling
pathway in OBs35. PTH activates the cyclic adenosine mono-
phosphate (AMP)-dependent protein kinase A, the calcium-
dependent protein kinase C pathway, the mitogen activated
protein (MAP) kinase, and phospholipase C and D pathways35. PTH
also exerts indirect anabolic effects through the induction of rele-
vant growth factors systems on OB lineage cells, such as the IGF-152,
or the down-regulation of growth factor antagonists, such as the
Wnt-antagonists sclerostin53 and Dkk-154. Interestingly in the
present study, intermittent PTH [1-34] increased the subchondral
ratio OPG/RANKL compared with vehicle administration in OPOA
rabbits, suggesting this mechanism may contribute for the positive
balance in subchondral remodelling towards bone formation and to
subsequent improvement of the functional microstructure at sub-
chondral bone following PTH [1-34] administration. Noticeably,
a cross-talk between OPG and DDK-1 has been described, thus OPG
seems to be regulated by the Wnt system and vice versa55. Indeed,
the mutual inverse regulation between DDK-1 and OPG originates
that an increased OPG expression mediates the antiresorptive
actions on osteoclastogenesis and bone metabolism of DKK-1
inhibition. In the other hand, low levels of DKK-1 appear to be
crucial for osteophyte formation, while the RANKL/OPG system
may not be involved in this process55. Even, other less known PTH
mechanism of action on subchondral remodelling such as the
increased production of the anti-osteoclastogenic isoform RANKL3
by OA subchondral osteoblasts has been recently described56. In
this context, the potential role of the RANKL/RANK/OPG pathway in
subchondral bone remodelling has gained special attention19,56,57.
All these biological events reﬂex the intimate interplay between
anabolic and catabolic pathways in joint remodelling58. Thus, the
anabolic agent PTH [1-34] acting at microstructural, biochemical
and molecular levels improved the quality of OP subchondral bone
in our animal model of early OA associated with precedent OP.
It is not possible to exclude some direct beneﬁcial effects of the
intermittent PTH administration on the diseased cartilage59e61.
Indeed, this molecule has been recently shown to reverse the
decreased expression of glycosaminoglycan (GAG) and type II
collagen, the increased type X collagen expression and chondrocyte
apoptosis in knees of papain-induced OA rat model59. Furthermore,
PTH inhibited terminal differentiation in human chondrocytes
during the same study59. In addition, our group has shown
a reduction of the OPG/RANKL ratio in chondrocytes of OA patients,
and moreover, celecoxib increased it in human OA cartilage62.
Lastly, good correlations were established between parameters
of microstructure and remodelling at subchondral bone, and
M. Bellido et al. / Osteoarthritis and Cartilage 19 (2011) 1228e12361234moreover, a similar strong correlation was observed between
microstructure and remodelling parameters at subchondral bone
and the cartilage damage score. Thus, the improvement of
microstructure and remodelling at OP subchondral bone following
the treatment with the anabolic agent PTH, initiated at 5 weeks
after joint surgery (time point of the development of earliest
cartilage lesions), would markedly contribute to avoid the
progression of cartilage damage in our experimental model
of OPOA.
It should be acknowledged, however, that the most obvious
weakness of the present study lies on the suitability of the exper-
imental model for the study of subchondral bone and cartilage
changes in a surgical-induced OAwith precedent OP10, which could
be observed only in a subset of OA patients. Nevertheless, these
data might have also some relevance for OA alone since similar
impaired microstructure and increased remodelling at subchondral
bone have been described in early OA stage in both human and
animal models4e7,28,63,64. As matter of fact, a complex relationship
between subchondral bone and articular cartilage during OA initi-
ation and progression elicits an unresolved question with valuable
therapeutical implications65.
Therefore, the current study provides the ﬁrst evidence that the
improvement of microstructural and remodelling parameters at OP
subchondral bone by the administration of an anabolic agent at an
early stage of OA markedly contribute to prevent cartilage damage
progression. Our results support the relevance of the role of
the subchondral bone in the OA process, and suggest that bone-
forming agents such as PTH might hold a place in the treatment for
early OA, particularly when OA is associated with OP. Continued
investigation in animal models and future clinical studies
will help us to advance our understanding of the inﬂuence of
changes in subchondral and systemic bone metabolism on the
course of OA.
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